Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner

Ensysce Biosciences, Inc.

Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.
PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.
FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.